Xvivo Perfusion AB (publ) (XVIVO.ST)
SEK 465.0
(1.97%)
SEK 465.0
(1.97%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 21.16 Million SEK | 375.17% |
| 2022 | 4.45 Million SEK | 192.71% |
| 2021 | 1.52 Million SEK | -53.68% |
| 2020 | 3.28 Million SEK | 52.55% |
| 2019 | 2.15 Million SEK | 0.0% |
| 2018 | - SEK | 0.0% |
| 2017 | - SEK | 0.0% |
| 2016 | - SEK | 0.0% |
| 2015 | - SEK | 0.0% |
| 2014 | - SEK | 0.0% |
| 2013 | - SEK | 0.0% |
| 2012 | - SEK | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 17.12 Million SEK | 0.0% |
| 2024 Q3 | - SEK | 0.0% |
| 2024 Q1 | 19.91 Million SEK | 0.0% |
| 2023 FY | 21.16 Million SEK | 375.17% |
| 2023 Q3 | 16.07 Million SEK | -90.59% |
| 2023 Q2 | 170.73 Million SEK | 6.92% |
| 2023 Q4 | 21.16 Million SEK | 31.73% |
| 2023 Q1 | 159.68 Million SEK | 3484.38% |
| 2022 Q4 | 4.45 Million SEK | 221.2% |
| 2022 Q1 | 1.63 Million SEK | 7.23% |
| 2022 FY | 4.45 Million SEK | 192.71% |
| 2022 Q3 | 1.38 Million SEK | -25.99% |
| 2022 Q2 | 1.87 Million SEK | 14.83% |
| 2021 FY | 1.52 Million SEK | -53.68% |
| 2021 Q1 | 2.16 Million SEK | -34.27% |
| 2021 Q2 | 1.64 Million SEK | -23.8% |
| 2021 Q3 | 746 Thousand SEK | -54.68% |
| 2021 Q4 | 1.52 Million SEK | 104.02% |
| 2020 Q2 | 2.58 Million SEK | -36.05% |
| 2020 Q3 | 1.56 Million SEK | -39.57% |
| 2020 Q4 | 3.28 Million SEK | 110.37% |
| 2020 Q1 | 4.04 Million SEK | 87.65% |
| 2020 FY | 3.28 Million SEK | 52.55% |
| 2019 Q4 | 2.15 Million SEK | -28.44% |
| 2019 FY | 2.15 Million SEK | 0.0% |
| 2019 Q1 | 4.57 Million SEK | 0.0% |
| 2019 Q2 | 3.92 Million SEK | -14.16% |
| 2019 Q3 | 3.01 Million SEK | -23.39% |
| 2018 Q3 | 3.29 Million SEK | -0.12% |
| 2018 FY | - SEK | 0.0% |
| 2018 Q1 | 3.3 Million SEK | 0.0% |
| 2018 Q2 | 3.29 Million SEK | -0.09% |
| 2018 Q4 | - SEK | -100.0% |
| 2017 FY | - SEK | 0.0% |
| 2017 Q1 | 3.13 Million SEK | 0.0% |
| 2017 Q2 | 3.16 Million SEK | 0.99% |
| 2017 Q3 | 3.19 Million SEK | 1.01% |
| 2017 Q4 | - SEK | -100.0% |
| 2016 Q1 | - SEK | 0.0% |
| 2016 Q4 | - SEK | 0.0% |
| 2016 Q2 | - SEK | 0.0% |
| 2016 Q3 | - SEK | 0.0% |
| 2016 FY | - SEK | 0.0% |
| 2015 Q1 | - SEK | 0.0% |
| 2015 Q2 | - SEK | 0.0% |
| 2015 Q4 | - SEK | 0.0% |
| 2015 FY | - SEK | 0.0% |
| 2015 Q3 | - SEK | 0.0% |
| 2014 Q1 | - SEK | 0.0% |
| 2014 Q2 | - SEK | 0.0% |
| 2014 Q3 | - SEK | 0.0% |
| 2014 Q4 | - SEK | 0.0% |
| 2014 FY | - SEK | 0.0% |
| 2013 Q4 | - SEK | 0.0% |
| 2013 Q2 | - SEK | 0.0% |
| 2013 FY | - SEK | 0.0% |
| 2013 Q1 | - SEK | 0.0% |
| 2013 Q3 | - SEK | 0.0% |
| 2012 Q4 | - SEK | 0.0% |
| 2012 FY | - SEK | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Acarix AB (publ) | - SEK | -Infinity% |
| ADDvise Group AB (publ) | 1.45 Billion SEK | 98.547% |
| ADDvise Group AB (publ) | 1.45 Billion SEK | 98.547% |
| Arcoma AB | 1.92 Million SEK | -998.547% |
| Bactiguard Holding AB (publ) | 42.3 Million SEK | 49.962% |
| BICO Group AB (publ) | 1.75 Billion SEK | 98.794% |
| Boule Diagnostics AB (publ) | 57.7 Million SEK | 63.312% |
| CellaVision AB (publ) | 28.66 Million SEK | 26.148% |
| Clinical Laserthermia Systems AB (publ) | 223 Thousand SEK | -9392.825% |
| Chordate Medical Holding AB (publ) | - SEK | -Infinity% |
| C-Rad AB (publ) | 1.75 Million SEK | -1107.587% |
| Duearity AB (publ) | 2.94 Million SEK | -620.034% |
| Dignitana AB (publ) | 6.07 Million SEK | -248.346% |
| Episurf Medical AB (publ) | 2.3 Million SEK | -820.391% |
| Getinge AB (publ) | 3.9 Billion SEK | 99.458% |
| Scandinavian Real Heart AB (Publ) | 6.35 Million SEK | -233.217% |
| Iconovo AB (publ) | 4.9 Million SEK | -331.413% |
| Integrum AB (publ) | 4.84 Million SEK | -336.965% |
| Luxbright AB (publ) | 206.02 Thousand SEK | -10175.017% |
| Mentice AB (publ) | 2.14 Million SEK | -887.36% |
| OssDsign AB (publ) | 214 Thousand SEK | -9792.056% |
| Paxman AB (publ) | 2.53 Million SEK | -736.058% |
| Promimic AB (publ) | - SEK | -Infinity% |
| Qlife Holding AB (publ) | 3 Million SEK | -604.694% |
| SciBase Holding AB (publ) | 4.17 Million SEK | -406.557% |
| ScandiDos AB (publ) | - SEK | -Infinity% |
| Sectra AB (publ) | 19.2 Million SEK | -10.232% |
| Sedana Medical AB (publ) | 1.01 Million SEK | -1991.798% |
| Senzime AB (publ) | 8.57 Million SEK | -146.782% |
| SpectraCure AB (publ) | 4.39 Million SEK | -381.442% |
| Stille AB | 38.06 Million SEK | 44.389% |
| Vitrolife AB (publ) | 1.87 Billion SEK | 98.871% |